Kangstem Biotech Co. Ltd (217730) — Cash Flow-to-Debt Ratio
Kangstem Biotech Co. Ltd (217730) has a Cash Flow-to-Debt Ratio of -0.42x as of June 2026, meaning its operating cash flow of ₩-4.93 Billion could theoretically repay 0% of its total liabilities (₩11.86 Billion) in one year. See 217730 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kangstem Biotech Co. Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Kangstem Biotech Co. Ltd across 11 annual periods. For the full cash flow conversion analysis, see Kangstem Biotech Co. Ltd operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Kangstem Biotech Co. Ltd (2015–2025)
Year-by-year debt coverage analysis for Kangstem Biotech Co. Ltd. Check cash flow quality index of Kangstem Biotech Co. Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.94x | ₩-11.68 Billion | ₩12.43 Billion | ▲ +36.7% |
| 2024 | -1.48x | ₩-18.99 Billion | ₩12.80 Billion | ▼ -230.2% |
| 2023 | -0.45x | ₩-16.50 Billion | ₩36.74 Billion | ▲ +20.6% |
| 2022 | -0.57x | ₩-18.86 Billion | ₩33.33 Billion | ▼ -16.8% |
| 2021 | -0.48x | ₩-16.99 Billion | ₩35.07 Billion | ▼ -6.9% |
| 2020 | -0.45x | ₩-13.99 Billion | ₩30.89 Billion | ▼ -46.0% |
| 2019 | -0.31x | ₩-13.32 Billion | ₩42.92 Billion | ▲ +31.0% |
| 2018 | -0.45x | ₩-11.48 Billion | ₩25.50 Billion | ▲ +5.2% |
| 2017 | -0.47x | ₩-10.65 Billion | ₩22.44 Billion | ▼ -48.9% |
| 2016 | -0.32x | ₩-7.80 Billion | ₩24.46 Billion | ▲ +68.6% |
| 2015 | -1.01x | ₩-3.80 Billion | ₩3.75 Billion | — |